MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc., (Worldwide) an award-winning, full-service, midsize, global CRO, announced today that Philippa Marshall, MD, BSc, FFPM, has joined the company as Vice President, Scientific Solutions, focused on immune-mediated inflammatory disorders (IMID).
With a career spanning more than 30 years in the biopharma industry and in contract research organizations (CROs), Dr. Marshall is a recognized specialist in internal medicine with emphasis in immunology, rare diseases and various pediatric indications. She has served in leadership roles with SmithKline Beecham (GSK), Novo Nordisk, Zambon, Quintiles (IQVIA), PharmaNet (inVentiv Health), and PPD.
“Dr. Marshall brings an unwavering dedication to advancing science and medicine and nearly three decades of therapeutic expertise to our expanding Scientific Solutions team,” said Peter Benton, president and COO, Worldwide Clinical Trials. “She will play a key role in providing the innovative insight our customers have come to expect from a CRO of our size. There’s really no substitute for the uncommon combination of world-class therapeutic expertise, global operations and personalized attention our team delivers.”
A graduate of University of Leeds with degrees in pharmacology (BSc) and medicine (MB ChB), Dr. Marshall is widely published and has given presentations at medical conferences throughout Europe and North America. She holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians and has been made a fellow of the college. Dr. Marshall’s medical experience includes transplantation medicine and surgery, general surgery, gastroenterology, respiratory medicine, neurology, cardiology (pediatrics), infectious diseases (pediatrics), and accident and emergency medicine.
For more information on Dr. Marshall and the expanding Scientific Solutions team at Worldwide Clinical Trials, visit www.worldwide.com.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.
